Date:10/21/2008

lease, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

China Pharma Holdings, Inc.

Diana Huang

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

The Ruth Group

Sara Ephraim

Tel: +1-646-536-7002

Email: sephraim@theruthgroup.com

'/>"/>

SOURCE China Pharma Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. CFO of China Yingxia Emphasizes Growth in Organic and Health Food Segment in Interview by The Wall Street Transcript
2. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
3. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
4. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
5. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
6. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
7. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
8. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
9. China Medicine to Showcase Bethin Weight Loss Product at 2008 Natural Products Expo East Trade Show
10. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
11. China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.